| Chronic Lymphocytic Leukemia |
1 |
1 |
| Chemotherapy |
0 |
0.67 |
| Biologic Therapy |
0 |
0.64 |
| Skin Cancer |
0 |
0.6 |
| Leukemia |
0 |
0.57 |
| Breast Cancer |
0 |
0.48 |
| Thrombocytopenia |
0 |
0.48 |
| Lung Cancer |
0 |
0.46 |
| Cancer |
0 |
0.42 |
| Prostate Cancer |
0 |
0.4 |
| Toxicology |
0 |
0.33 |
| Tyrosine Kinase Inhibitor |
0 |
0.24 |
| Non-Hodgkin Lymphoma (NHL) |
0 |
0.23 |
| B-Cell Lymphoma |
0 |
0.18 |
| Tumor Lysis Syndrome |
0 |
0.18 |
| Lymphoma |
0 |
0.17 |
| Remission |
0 |
0.17 |
| Residual Disease |
0 |
0.17 |
| Tumor |
0 |
0.17 |
| Tyrosine Kinase |
0 |
0.17 |
| Healthcare and Medical Technology |
0 |
0.09 |
| Melanoma |
0 |
0.09 |
| Neutropenia |
0 |
0.09 |
| Breast |
0 |
0.08 |
| Clinical Research |
0 |
0.08 |
| Europe |
0 |
0.08 |
| Hematology |
0 |
0.08 |
| Hospital |
0 |
0.08 |
| Immunoglobulin A (IgA) |
0 |
0.08 |
| Immunotherapy |
0 |
0.08 |
| Lung |
0 |
0.08 |
| Lymph Node |
0 |
0.08 |
| Monoclonal Antibody |
0 |
0.08 |
| Prognosis |
0 |
0.08 |
| Prostate |
0 |
0.08 |
| Texas |
0 |
0.08 |